BresaGen
Thebarton
About BresaGen
BresaGen is a developer of proteins and peptides, especially biogenerics. In October 2006, BresaGen was sold to Hospira Inc of the US, and Paragon made a 2.35x return on investment, and 135% IRR. Hospira acquired the company to further develop BresaGen’s intellectual property, and to distribute its products in the US.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Funding stage: M&A
- Last round: Private Equity (Aug 2005)
- Website: bresagen.com.au
- Phone: +61882342660
Industries & Categories
Biopharma, Biotechnology
Canonical: https://fsome.com/organization/bresagen-2147620 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.